Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

Global Summit on Heart Diseases and Therapeutics

Chicago, USA

 William Cromwell

William Cromwell

Lipoprotein & Metabolic Disorders Institute, USA

Title: Use of particle number versus cholesterol measures to optimize management of LDL-related ASCVD risk

Biography

Biography: William Cromwell

Abstract

Managing low-density lipoprotein (LDL) is an integral part of clinical practice. Recent guidelines have shifted from attaining discrete LDL goals (based on an individual’s cardiovascular disease risk), to use of specific therapies shown to reduce atherosclerotic cardiovascular disease (ASCVD) events in randomized controlled trials. Following institution of outcome proven therapy, on-treatment LDL levels are advocated to judge adherence, individual response, and aid consideration of adjustments to therapy. What remains controversial is whether LDL-guided adjustments in treatment can lead to further reduction in ASCVD events. Historically, the cholesterol content of LDL particles (LDL-C) has been used to express LDL quantity. However, due to variability in the cholesterol carried in LDL particles, frequent disagreement (discordance) occurs between LDL-C and particle number measures of LDL quantity, including apolipoprotein B-100 (apo B) or nuclear magnetic resonance (NMR) LDL particle number (LDL-P). Epidemiologic and clinical intervention trials consistently demonstrate that ASCVD risk tracks with LDL particle number (apo B or NMR LDL-P), rather than LDL-C, when these measures are discordant. Furthermore, managed care claims data demonstrate significant additional reduction of ASCVD events is noted among high-risk patients attaining low NMR LDL-P (mean 860 nmol/L) versus statin treated subjects with low LDL-C (mean 79 mg/dL). Accordingly, many expert society recommendations and guidelines now advocate use of LDL particle number (NMR LDL-P or apo B) to adjudicate individual response and aid adjustment in therapy to optimize individual therapy.